CN1470250A - External-use disinfecting medicinal preparation for women - Google Patents
External-use disinfecting medicinal preparation for women Download PDFInfo
- Publication number
- CN1470250A CN1470250A CNA021335192A CN02133519A CN1470250A CN 1470250 A CN1470250 A CN 1470250A CN A021335192 A CNA021335192 A CN A021335192A CN 02133519 A CN02133519 A CN 02133519A CN 1470250 A CN1470250 A CN 1470250A
- Authority
- CN
- China
- Prior art keywords
- effect
- medicament
- women
- oligose
- external
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims description 16
- 230000000249 desinfective effect Effects 0.000 title claims description 8
- 239000003814 drug Substances 0.000 claims abstract description 24
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims abstract description 8
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims abstract description 8
- -1 hydroxybenzoate ester Chemical class 0.000 claims abstract description 8
- 229960002510 mandelic acid Drugs 0.000 claims abstract description 8
- 229920001542 oligosaccharide Polymers 0.000 claims description 9
- 150000002482 oligosaccharides Chemical class 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 4
- 239000004327 boric acid Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 25
- 230000002147 killing effect Effects 0.000 abstract description 12
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 9
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 239000000645 desinfectant Substances 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 241000223996 Toxoplasma Species 0.000 abstract description 2
- 230000009471 action Effects 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 241001502500 Trichomonadida Species 0.000 abstract 1
- 230000009982 effect on human Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000007096 poisonous effect Effects 0.000 abstract 1
- 230000000284 resting effect Effects 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 14
- 206010046914 Vaginal infection Diseases 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000001215 vagina Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 208000037009 Vaginitis bacterial Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 201000008100 Vaginitis Diseases 0.000 description 7
- 240000001046 Lactobacillus acidophilus Species 0.000 description 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 5
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 229940095731 candida albicans Drugs 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000007938 effervescent tablet Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010018612 Gonorrhoea Diseases 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 229920001607 Policresulen Polymers 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 208000001786 gonorrhea Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- ACZKMKGNTMOPBD-UHFFFAOYSA-N policresulen Chemical compound CC1=CC(O)=C(S(O)(=O)=O)C=C1CC1=CC(S(O)(=O)=O)=C(O)C(CC=2C(=CC(O)=C(C=2)S(O)(=O)=O)C)=C1C ACZKMKGNTMOPBD-UHFFFAOYSA-N 0.000 description 2
- 229960002954 policresulen Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960005053 tinidazole Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- XWBADQOPXPRKBX-FMIVXFBMSA-N 1-n,1-n-diethyl-4-n-[6-methoxy-2-[(e)-2-(4-nitrophenyl)ethenyl]quinolin-4-yl]pentane-1,4-diamine Chemical compound N=1C2=CC=C(OC)C=C2C(NC(C)CCCN(CC)CC)=CC=1\C=C\C1=CC=C([N+]([O-])=O)C=C1 XWBADQOPXPRKBX-FMIVXFBMSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003716 antitrichomonal agent Substances 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003077 cycloserine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000008921 jie er yin Substances 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 235000015073 liquid stocks Nutrition 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- WYMSBXTXOHUIGT-UHFFFAOYSA-N paraoxon Chemical compound CCOP(=O)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 WYMSBXTXOHUIGT-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000002423 protozoacide Substances 0.000 description 1
- 229940068944 providone-iodine Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention is a female external disinfectant medicament. The components contain the following mian raw materials according to weight percent, and the raw materials are prepared into medicament: hydroxybenzoate ester 2-40%, mandelic acid 3-50%, lacidophihin 10-55% and oligose 8-50%. It is a new compound disinfectant medicament, its antibacterial effect mainly inhibiting the activity of the inner aspiratory enzyme of microbe cell and the electronic transfer enzyme system, and has the effect of destroying the permeation of microbe cell film, its antibacterial character: it has strong action on mildew and yeast mushroom. The mandelic acid has very strong activity of killing the protozoons like trichomonad and toxoplasma. The oligose is a indigestible sugar without any poisonous side effect on human body. The lacidophihin and oligose as micro-ecological regulator has remarkale "the effect of resting and benefiting".
Description
Technical field
The present invention relates to the pharmaceuticals technical field, specifically external-use disinfecting medicinal preparation for women.
Background technology
Vaginitis is the frequently-occurring disease of gynecological, from the classification of nosetiology angle, can be divided into colpitis mycotica, trichomonal vaginitis, bacterial vaginosis (bacterial vaginosis, BV; Be called nonspecific vaginitis in the past, non-specific vaginitis, NSV), senile vaginitis and gonorrhea, syphilis etc., though wherein preceding four class vaginitiss do not have gonorrhea, syphilis so serious on the state of an illness, but sickness rate is very high, the course of disease is long, and being easy to recurrence, also can the trafficability characteristic behavior propagating simultaneously, is to have a strong impact on the able-bodied commonly encountered diseases of numerous women.
Colpitis mycotica, trichomonal vaginitis, bacterial vaginosis and senile vaginitis are four kinds of commonly encountered diseases, and its pathogenetic common inducement is: the decline of vagina local immunity power, micro-ecological bacterial group imbalance, heavy dose or the treatment of prolonged application extensive pedigree antibiotic, use " system kills type " disinfectant, bad hygienic habit irrelevantly and factor such as spread through sex intercourse; On nosetiology, mycotic and trichomonal vaginitis have specific pathogen, and bacterial vaginosis and senile vaginitis mostly are the mixed infection of endogenous obligate anaerobe and facultative anaerobe, promptly, be that vagina often occupies due to the unusual breedings of a certain class in the flora or number class conditioned pathogens, as gardnerella vaginalis (modal conditioned pathogen), mycoplasma, golden Portugal bacterium, escherichia coli etc.; Aspect organic factor, young and middle-aged married women is in premenstrua and trimester of pregnancy, because the vagina estrogen level increases, make the interior glycogen levels of vagina epithelium increase, bring out colpitis mycotica and bacterial vaginosis easily, women after senile vaginitis then is mainly in menopause, because women's ovarian function of this age bracket is degenerated, body inner estrogen level reduces, the partial pH rising of vagina (pH5.8~6.8), thereby the helpfulness flora in the microecology in vaginas flora reduces, the self purification of vagina goes down, and is referred to as atrophic vaginitis again.Therefore, whether closely related factor such as situation of intravaginal estrogen level, glycogen content, pH value and micro-ecological bacterial clump and above-mentioned all kinds of colpitic morbidity be.In addition, above-mentioned four kinds of vaginitiss all have the characteristics of outbreak repeatedly clinically, and, the patient of significant proportion does not have conscious malaise symptoms, but its clinical consequences is quite serious, especially repeatedly outbreak or chronic bacterial vaginosis, very easily concurrent cervicitis, fallopian tube and ovary infection, pelvic inflammatory disease etc. also are the common causes that the women loses fertility.
In sum, vaginitis is to have a strong impact on able-bodied commonly encountered diseases of women and frequently-occurring disease.Because China is populous, and cultural quality is relative with hygienic habit backward, and the sexual behaviour knowledge of Gynecological health and health is relatively deficienter, the influence of traditional culture and constraint in addition, make a large amount of patients in time not obtain medical treatment, actual diseased person's prescription on individual diagnosis rate less than 20~30%.Simultaneously, shortage system, macroscopic microecological balance idea in the guidance of prevention and treatment, application antibiotics blindly and " system is type extremely " disinfectant, consequently vicious cycle that " rises one after another ".In recent years, though numerous scholars and hygiene department have recognized the severe situation of China's abuse of antibiotics, still, solve this phenomenon and need time and a large amount of popular science propaganda education.
At present, domestic prevention of having developed reaches over one hundred kind more than with all kinds of colpitic preparations of treatment, also the reaching of market circulation tens of kinds (wherein not comprising the various conventional antibiotics of using).On the route of administration of product, can be divided into general medication and local application's preparation; The accurate word of medicine is arranged, defend the accurate word that disappears, defend and make up word and the strong word of medicine etc. from the attribute of preparation; On the purposes of product, existing single sick preparation of planting (as the miconazole of antifungal etc.), the preparation (as metronidazole, tinidazole, JIEERYIN etc.) for the treatment of infusorian and bacterial vaginosis is simultaneously also arranged; From the prescription composition of preparation, single composition is arranged, compound preparation is also arranged, wherein mainly be divided into: antifungal drug is (as imidazoles, the polyenoid class), anti-bacterial drug is (as beta-lactam, aminoglycoside, macrolide, quinolones etc.), Chinese medicine is (as Radix Sophorae Flavescentis, Fructus Cnidii, garlicin, Rhizoma Coptidis, Radix Et Rhizoma Rhei, Cortex Pseudolaricis, the Fructus Kochiae, dried Alumen, tens of kinds of Herba Houttuyniae etc.), quaternary ammonium salt surface active agent, acetic acid, propanoic acid, salicylic acid, boric acid, policresulen (policresulen), povidone iodine (providone-iodine) and contain lactobacillus or the compound disinfecting medicament of lactein; On the preparation form of local application, can be divided into suppository, washing liquid, effervescent tablet, capsule, powder, cream, spray etc.
Because vaginitis is the global women's of puzzlement common disease, both just in the highly developed like this country of the U.S., vaginitis is still one of 25 kinds of commonly encountered diseases.Therefore, are one of important topics of medical circle to all kinds of colpitic effective controls.In present afloat all kinds of control agent, metronidazole or tinidazole are the trichomonal vaginitis of generally acknowledging and effective therapeutic agent of bacterial vaginosis, and still, their side effect also receives publicity day by day.Generally speaking, one time the user has 10~20% people to occur feeling sick and parageusia approximately, take for a long time and very easily cause colpitis mycotica and superinfection, wherein, when administration 2 days and 7 days, the concurrent colpitis mycotica of 6~8% and 26% patient is arranged respectively, and nervous system is caused damage, in the part or systemic treatment in pregnancy period, also serious consequences such as habitual abortion, stillborn fetus can appear.Imidazoles (as ketoconazole, econazole, fluconazol, clotrimazole etc.), polyenoid class (as amphotericin B, nystatin etc.) are the active drugs for the treatment of colpitis mycotica at present, but its toxic and side effects and treatment back high relapse rate are also generally acknowledged.
Summary of the invention
The purpose of this invention is to provide a kind of selective antibiotic with microecology and antibacterials and act as basic foundation, the common vaginitis that mycete, infusorian, vaginal flora disorder etc. are brought out has the external-use disinfecting medicinal preparation for women of preventive and therapeutic effect.
The present invention is in conjunction with domestic and international relevant progress, the experimentation and the demonstration of system have been carried out in aspects such as inside and outside bactericidal effect, toxicological safety, stability of formulation, production technology and quality standard at product attribute and functional localization, pathogenic microbes, drawn the present invention, concrete technical scheme is:
Contain following weight percentages in the key component, and be prepared into medicament: hydroxybutyric acid ester 2~40%, mandelic acid 3~50%, lactein 10~55%, oligosaccharide 8~50%.
Described medicament is the above a dosage form of any pharmaceutics, can be spray, washing liquid and effervescent tablet.
When making tablet, also contain following percentage by weight adjuvant in the component: boric acid 50~85%, sodium bicarbonate 10~40%, magnesium stearate 0.5~8% excipient.
The present invention is as the novel disinfectant of a compound type, antibiotic property composition p-Hydroxybenzoate in the Main Ingredients and Appearance, be through being widely used as the material of food preservative decades, prove its no obvious toxic-side effects, its antibacterial action mainly is the activity that suppresses microbial cell internal respiration enzyme and electron transport enzyme system, and the effect of destroy microorganisms membrane permeability arranged, suppress and the effect of killing certain micro-organisms thereby reach, its antimicrobial spectrum characteristics are strong to mycete and yeast-like fungi effect, and it is relative relatively poor, even invalid to the effect of bacillus acidophilus and Anaerobic Bacteria.Mandelic acid system in the prescription is by the natural product that extracts purification in the rosaceous plant leaf of Fructus Persicae, have very strong protozoacide activity such as infusorian, toxoplasma extremely, the effect of lactein is systematically discussed in preamble, and oligosaccharide FOS is the bacillus bifidus multiplicaiton factor of generally acknowledging in the world, it can reach 10~100 times height to the proliferate efficiency of endogenous bacillus bifidus, be to human body indigestion saccharide without any side effects, lactein and oligosaccharide (oligosaccharide) have significantly " supporting the benefit effect " as microecologic regulator.
So, in prevention and all kinds of colpitic methods of treatment and measure, combine with the microecological environment of safeguarding vaginal health with " selective antibiotic ", meet current and future science developing direction, its science also is well grounded with advance.
The mechanism of action of main antibacterials of table 4. and the true product of the present invention
The mechanism of action of this product of effect of main antibacterials commonly used
Change the thin plant interference cell of thin influence influence influence albumen influence thin biological antagonist bifid because of
The synthetic born of the same parents' metabolism jizi for making dumplings of the synthetic matter of the penetrating nucleic acid syncytial virus of after birth internal respiration insects wall
Property becomes the enzyme agent
To the hydroxyl β-sharp good fortune sulfonamides of Nei many Acarasiales of acyl Aminoglycoside almond
Flat (TMP) acid of the plain class class of benzoic acid lactein oligosaccharide amine
Ester
(also
Macrolide quinoline promise ethamine fourth changes thin vancomycin imidazoles
Class ketone alcohol after birth knot
Structure)
To amino cycloserine polyenoid class Tetracyclines
Salicylic acid
Pyrazine acyl bacitracin chloromycetin
Amine
The ground acid of furan west
The in-vitro antibacterial of medicament of the present invention (vagina effervescence) and infusorian effect extremely
1. materials and methods
Tried bacterium (worm) strain: Candida albicans ATCC 10231, the golden bacterium ATCC of Portugal 25923, escherichia coli ATCC 25922 and bacillus acidophilus ATCC 314, with the 3rd~8 generation culture for being tried bacterium; Trichomonal vaginitis clinical strain (3 strain) for after the rejuvenation the 3rd generation culture; Various objectives bacterium and worm strain increase bacterium through liquid meat soup, cultivate suspension for being tried bacterium (worm) strain with the worm strain of logarithmic (log) phase bacteria suspension and 12h; Culture medium method is as described above selected for use.It dissolves that (concentration is: 50 are dissolved in 100ml to effervescent tablet with appropriate solvent and cosolvent, be 25mg/ml), pH is adjusted to 2.5 ± 0.5, and be mixed with the test medicinal liquid, and this medicinal liquid is made four dilution factors of 1,2,4,6 times of dilution, and effect is tried 1,2,4,5 hours four times of bacterium (worm) strain respectively, after removing medicine, tried bacterium and be inoculated in each purpose bacterium test agar flat board, cultivated 48~72h, observed result for 35 ℃; Tried the worm strain and directly used the ultramicroscopic observation mobility, granulating and polypide ulceration rate.Establish positive control (no medicine group) and negative control (blank culture medium) respectively.
2. result: see the following form.
Qualitative sterilization (worm) result of the test of medicament of the present invention (washing liquid)
Tried bacterium (1.5 * 10 6 Cfu/ml), the worm strain (5 * 10 4 Individual/ml) with action time (h)Concentration/contrast Candida albicans staphylococcus aureus escherichia coli bacillus acidophilus's infusorian clinical strain (dilution factor)
ATCC 10231 ATCC 25923 ATCC 25922 ATCC314
1 2 4 5 ( h ) 1 2 4 5 ( h ) 1 2 4 5 ( h ) 1 2 4 5 ( h ) 1 2 4 5 ( h ) ×1 100%×2 100%×4 + +--100%×6 + + +-+ + +-+ +--+ + + + 100% :48-72h“”“”,“+”“-”; Worm strain mortality rate is represented with %.Liquid stock solution is pressed embodiment 2 preparations 3. interpretations of result
This dosage form medicinal liquid is tried pathogen in the stock solution of experimental concentration, 2 times of dilutions and 4 times of diluted concentrations to 3 strains and is all possessed inhibition or dissipation effect fully, and trichomonacide is had 100% killing action.
This dosage form medicinal liquid has the bacillus acidophilus in stock solution and 2 times of diluted concentrations and to suppress fully or killing action, but only presents bacteriostatic activity when 4 times and 6 times of diluted concentrations.Explanation is weaker than pathogen to the antibacterial action of lactobacillus.
The microorganism killing test of medicament of the present invention
Medicament stock solution of the present invention was to escherichia coli effect 10 minutes, and average kill ratio is 100%, and to staphylococcus aureus effect 15 minutes, average kill ratio was 99.98%; To Candida albicans effect 15 minutes, average kill ratio was 99.99%.Medicament was deposited in 37 ℃ of incubators after 90 days, and to escherichia coli effect 10 minutes, average kill ratio was 99.99.Meet GB15981-1995 standard (killing rate 〉=99.9%) regulation.
Medicament stock solution of the present invention acts on 15 minutes to the bacillus acidophilus, and average kill ratio is 61.50%; To bacillus bifidus effect 15 minutes, average kill ratio was 65.80%, and the result that examines does not meet GB15981-1995 standard (killing rate 〉=99.9%) regulation.
The above results illustrates that medicinal liquid of the present invention has the selectively killing effect to microorganism.Pathogenic bacterium (staphylococcus aureus, Candida albicans etc.) had significant killing action, and the killing rate of beneficial bacteria in the human body (bacillus acidophilus, bacillus bifidus) is not met GB15981-1995 standard (killing rate 〉=99.9%) regulation, promptly the killing action to beneficial bacteria is invalid.
The acute oral toxicity experiment of medicament of the present invention (spray)
One, material and animal
1, tried thing: washing liquid of the present invention, sample are light brown liquid.
2, animal: Kunming kind white mice, body weight 18-21.5g is provided (the animal quality certification number: No. the 9712nd, the real moving card in Yunnan) by Chinese Academy of Sciences's Kunming zooscopy.
Two, method
1. test basis: " disinfection technology standard " third edition first fascicle 3.4 acute orals poison test.
2. test method:
Mensuration, dosage is established 20000mg/kg, gets 20 animals, and male and female half and half are irritated the preceding animal of stomach
Fasting 12 hours, one time per os is irritated stomach, observes record animal poisoning symptom continuously 14 days
And death condition.
Three, experimental result:
Animal subject is at viewing duration, and not seeing has obvious poisoning symptom, does not see death.
Four, conclusion
Under this experiment condition, tried thing (spray of the present invention) animal subject white mice per os toxicity test is pressed anxious toxicity LD
50The dosage grade scale is judged to be actual nontoxic.
Specific embodiments
Embodiment 1:
Get percentage by weight raw material hydroxybutyric acid ester 8%, mandelic acid 36%, lactein 30%, it is standby that oligosaccharide 26% is hybridly prepared into major ingredient; Reuse boric acid 78%, sodium bicarbonate 20%, magnesium stearate 2% is hybridly prepared into adjuvant; With the major ingredient for preparing and adjuvant by 4: 1 mixed after, make the vagina effervescence tablet with existing method.
Embodiment 2:
Get percentage by weight raw material hydroxybutyric acid ester 25%, mandelic acid 18%, lactein 23%, it is standby that oligosaccharide 34% is hybridly prepared into major ingredient; Water, OP, propylene glycol etc. are prepared into non-ionic surface active agent according to a conventional method as solvent, and the dissolving major ingredient is mixed with the external spraying agent that concentration is 30mg/ml.
Embodiment 3:
Get percentage by weight raw material hydroxybutyric acid ester 21%, mandelic acid 19%, lactein 26%, it is standby that oligosaccharide 34% is hybridly prepared into major ingredient; Water, OP, propylene glycol etc. are prepared into non-ionic surface active agent according to a conventional method as solvent, and the dissolving major ingredient is mixed with the external wash liquid that concentration is 25mg/ml.
Claims (3)
1, a kind of external-use disinfecting medicinal preparation for women is characterized in that containing in the component main material of following weight percentage ratio, and is prepared into medicament: hydroxybutyric acid ester 2~40%, mandelic acid 3~50%, lactein 10~55%, oligosaccharide 8~50%.
2, external-use disinfecting medicinal preparation for women according to claim 1 is characterized in that described medicament is the above a dosage form of any pharmaceutics.
3, external-use disinfecting medicinal preparation for women according to claim 1 also contains following percentage by weight adjuvant: boric acid 50~85%, sodium bicarbonate 10~40%, magnesium stearate 0.5~8% excipient in the component when it is characterized in that making tablet.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02133519 CN1203868C (en) | 2002-07-23 | 2002-07-23 | External-use disinfecting medicinal preparation for women |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02133519 CN1203868C (en) | 2002-07-23 | 2002-07-23 | External-use disinfecting medicinal preparation for women |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1470250A true CN1470250A (en) | 2004-01-28 |
CN1203868C CN1203868C (en) | 2005-06-01 |
Family
ID=34145585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02133519 Expired - Fee Related CN1203868C (en) | 2002-07-23 | 2002-07-23 | External-use disinfecting medicinal preparation for women |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1203868C (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105362217A (en) * | 2015-11-25 | 2016-03-02 | 孙维星 | Conjunctival sac flushing fluid and preparation method thereof |
CN110585418A (en) * | 2018-06-13 | 2019-12-20 | 广州合伊美生物科技有限公司 | External use disinfection essential oil emulsion for women and production process thereof |
-
2002
- 2002-07-23 CN CN 02133519 patent/CN1203868C/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105362217A (en) * | 2015-11-25 | 2016-03-02 | 孙维星 | Conjunctival sac flushing fluid and preparation method thereof |
CN105362217B (en) * | 2015-11-25 | 2018-07-06 | 孙维星 | A kind of irrigation of conjunctival sac liquid and preparation method thereof |
CN110585418A (en) * | 2018-06-13 | 2019-12-20 | 广州合伊美生物科技有限公司 | External use disinfection essential oil emulsion for women and production process thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1203868C (en) | 2005-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102470117B (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof | |
CN110090195A (en) | A kind of women secret nursing gel and preparation method thereof | |
CN100509027C (en) | Nontoxic mucosal disinfectant containing isopropanol, oleum Sesami, Aloe and lemon oil | |
CN109985069B (en) | Probiotic compositions and uses thereof | |
CN109528982A (en) | A kind of ozone oleogel and preparation method thereof for gynaecological imflammation | |
RU2673737C2 (en) | Volatile organic compound formulations having antimicrobial activity | |
US11285122B2 (en) | Volatile organic compound formulations having antimicrobial activity | |
CN105232526A (en) | Application of medicine containing catechin to preparation of antibacterial medicines | |
CN1524587A (en) | Nursing wet towel using tea plant oil as antibacterial and fungistatic agent and production method thereof | |
CN102048729B (en) | Preparation for treating vaginitis | |
CN1203868C (en) | External-use disinfecting medicinal preparation for women | |
CN108404111A (en) | One kind is with kidney bean phytolectin inhibitory anti-virus preparation as main component | |
CN100592915C (en) | Ecological vagina cleaning bacteriostasis liquid | |
CN109464655A (en) | A kind of external-applied capsules preparation for preventing and treating vaginitis | |
CN107308104A (en) | A kind of preparation method of gynecological gel | |
BR112021005603A2 (en) | formulation, and, methods for treating or preventing a pathogenic or wound infection, treating or preventing an oral infection, treating or preventing infection during or following a medical procedure, treating or preventing a fungal infection, administering the formulation, maintaining or improving health of an animal and disinfect a surface | |
Houglum et al. | Drugs for Treating Infections | |
RU2248212C2 (en) | Preparation for treatment of bacterial vaginitis, method for its preparing and method for treatment of bacterial vaginitis | |
CN1062450C (en) | Formula and preparation process of lactobacillaceau embolus | |
CN1431012A (en) | Externally used Chinese herbal medicine for treating gynecology inflammation | |
CN1281271C (en) | Biological bacteria inhibitor | |
US12097173B2 (en) | Volatile organic compound formulations having antimicrobial activity | |
CN1528341A (en) | Povidone-iodine foamable composition | |
CN1270752C (en) | Antiseptic and its processing method | |
RU2802308C2 (en) | Compositions of volatile organic substances with antimicrobial activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050601 Termination date: 20210723 |